Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial dehydrogenase refers to a broad class of enzymes, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alanine dehydrogenase, that catalyze the removal of hydrogen atoms from substrates during bacterial metabolism. These enzymes are essential for energy production through pathways like glycolysis and the tricarboxylic acid (TCA) cycle, making them vital for bacterial survival and replication. In a therapeutic context, specific bacterial dehydrogenases are targeted by antimicrobial agents to disrupt metabolic homeostasis and induce cell death. For example, GAPDH from pathogens like Atopobium vaginae is explored as a druggable target due to its role in both metabolism and immunoevasion. Additionally, certain prodrugs like pretomanid require activation by bacterial deazaflavin-dependent enzymes with dehydrogenase-like activity to exert their bactericidal effects against Mycobacterium tuberculosis.
Inhibition of enzymatic activity leads to disruption of bacterial metabolism, depletion of ATP, and accumulation of toxic intermediates or reactive oxygen species, ultimately causing bacterial cell death.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial dehydrogenase.